Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The firm presently has a $1.25 price target on the biotechnology company’s stock. Zacks Investment Research‘s target price points to a potential upside of 19.05% from the company’s previous close.
According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “
BLPH has been the topic of a number of other research reports. ValuEngine downgraded Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 10th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Bellerophon Therapeutics in a research report on Wednesday, September 6th.
Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 1.05 on Friday. Bellerophon Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.69. The firm has a 50 day moving average price of $1.08 and a 200-day moving average price of $1.20. The company’s market cap is $37.29 million.
Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. Equities research analysts anticipate that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.
WARNING: “Zacks Investment Research Upgrades Bellerophon Therapeutics, Inc. (BLPH) to Buy” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://transcriptdaily.com/2017/09/17/zacks-investment-research-upgrades-bellerophon-therapeutics-inc-blph-to-buy.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. purchased a new stake in Bellerophon Therapeutics during the first quarter valued at about $125,000. Renaissance Technologies LLC increased its holdings in shares of Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock worth $711,000 after buying an additional 238,300 shares during the period. Vanguard Group Inc. increased its holdings in shares of Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock worth $821,000 after buying an additional 211,111 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of Bellerophon Therapeutics in the second quarter worth about $1,316,000. Institutional investors and hedge funds own 45.85% of the company’s stock.
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.